23 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27940419	31	Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands.	Comenius University In Bratislava
15080993	23	Novel GSK-3 inhibitors with improved cellular activity.	Glaxosmithkline
27474927	76	Synthesis, biological evaluation and molecular modeling studies of imidazo[1,2-a]pyridines derivatives as protein kinase inhibitors.	Paris-Sud University
26562543	14	Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease.	Central University
25827523	275	Isosteric replacements of the carboxylic acid of drug candidate VX-787: Effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors.	Vertex Pharmaceuticals
25198388	47	The design and synthesis of potent and selective inhibitors of Trypanosoma brucei glycogen synthase kinase 3 for the treatment of human african trypanosomiasis.	University of Dundee
20363627	56	Identification and structure-activity relationship of 8-hydroxy-quinoline-7-carboxylic acid derivatives as inhibitors of Pim-1 kinase.	Universit£
17303421	56	Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors.	Roche Research Center
16789733	41	Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.	Bristol-Myers Squibb Pharmaceutical Research Institute
16765046	63	Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.	Chiron
16366598	51	(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells.	Johnson & Johnson Pharmaceutical Research and Development
30639897	48	Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.	The First Affiliated Hospital of Zhengzhou University
31404862	138	Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases.	Palack£
30909021	21	Insights into the chemistry and therapeutic potential of furanones: A versatile pharmacophore.	Jamia Hamdard
31054862	14	1-Aryl-3-(4-methoxybenzyl)ureas as potentially irreversible glycogen synthase kinase 3 inhibitors: Synthesis and biological evaluation.	Stellenbosch University
23683591	23	Synthesis and evaluation of 8-amino-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives as glycogen synthase kinase-3 (GSK-3) inhibitors.	Jeil Pharmaceutical
15715498	7	CH...O and CH...N hydrogen bonds in ligand design: a novel quinazolin-4-ylthiazol-2-ylamine protein kinase inhibitor.	Vertex Pharmaceuticals
15686883	59	The development of potent and selective bisarylmaleimide GSK3 inhibitors.	Lilly Research Laboratories
15603961	35	3D QSAR studies on GSK-3 inhibition by aloisines.	Zhejiang University
29985601	64	Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.	Seoul National University
27689729	17	Natural and synthetic bioactive inhibitors of glycogen synthase kinase.	Jamia Hamdard (Hamdard University)